Teva Pharmaceutical Industries (TEVA) Operating Margin (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Operating Margin for 18 consecutive years, with 5.58% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Margin fell 1647.0% year-over-year to 5.58%; the trailing twelve-month figure through Jun 2026 stood at 9.26% (up 341.0% YoY), and the FY2025 full-year result was 12.5%, up 1433.0% from the prior year.
• Operating Margin declined to 5.58% in Q2 2026 per TEVA's latest filing, from 16.37% in the prior quarter.
• Across five years, Operating Margin topped out at 19.69% in Q3 2025 and bottomed at 25.54% in Q2 2022.
• Historically, Operating Margin has averaged 0.24% across 5 years, with a median of 0.24% in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Margin plunged 4043 bps in 2022, then jumped 4116 bps in 2023.
• Over 5 years, Operating Margin stood at 24.2% in 2022, then surged by 170 bps to 16.96% in 2023, then tumbled by 106 bps to 1.0% in 2024, then surged by 737 bps to 6.37% in 2025, then slumped by 188 bps to 5.58% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 5.58%, 16.37%, and 6.37% for Q2 2026, Q1 2026, and Q4 2025 respectively.